天新药业(603235) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥546,966,616.93, representing a 49.12% increase compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥149,314,516.53, an increase of 80.01% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥138,406,863.87, reflecting a 127.04% increase compared to the previous year[2] - Basic earnings per share for Q3 2024 were ¥0.34, up 78.95% from the same quarter last year[3] - Total operating revenue for the first three quarters of 2024 reached CNY 1,613,579,810.79, an increase of 8.5% compared to CNY 1,487,340,403.10 in the same period of 2023[13] - Net profit attributable to shareholders of the parent company for the third quarter of 2024 was CNY 494,482,977.97, up 19.7% from CNY 412,902,988.52 in the third quarter of 2023[17] - Basic and diluted earnings per share for the third quarter of 2024 were both CNY 1.13, compared to CNY 0.94 in the same quarter of 2023[17] - The net profit for the first three quarters of 2024 was ¥525,646,257.31, up 18.7% from ¥442,742,585.20 in the previous year[26] - The earnings per share for the first three quarters of 2024 was ¥1.20, compared to ¥1.01 in the same period of 2023, representing a growth of 18.8%[26] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥5,272,368,099.96, a 3.58% increase from the end of the previous year[3] - The equity attributable to shareholders increased by 5.29% to ¥4,456,661,809.73 compared to the end of the previous year[3] - The company's total assets increased to CNY 5,272,368,099.96, compared to CNY 5,090,159,178.34 at the end of the previous quarter[12] - The total liabilities decreased to CNY 815,706,290.23 from CNY 857,212,016.90 in the previous quarter[12] - The company's total current liabilities decreased to approximately ¥236.42 million as of September 30, 2024, down from ¥419.07 million at the end of 2023, indicating improved liquidity[23] - The total liabilities decreased to ¥599,495,071.28 from ¥809,423,974.11, reflecting a reduction of approximately 26%[24] - The total equity increased to ¥4,526,766,465.94, compared to ¥4,271,888,538.31, marking a growth of about 6%[24] Cash Flow - The net cash flow from operating activities for the year-to-date decreased by 24.81% to ¥439,852,434.45[2] - The net cash flow from operating activities for the first three quarters of 2024 was approximately ¥439.85 million, down 24.7% from ¥584.96 million in the same period of 2023[20] - The cash flow from operating activities generated a net amount of ¥183,023,573.88, down from ¥417,128,598.64 in the previous year[27] - The company's cash and cash equivalents at the end of September 2024 were approximately ¥1.62 billion, down from ¥2.40 billion at the end of 2023, reflecting a decrease of 32.3%[21] - The cash and cash equivalents at the end of the period decreased to ¥1,574,870,618.23 from ¥2,306,668,288.63, a decline of approximately 31.7%[28] - The net cash flow from financing activities was approximately -¥278.71 million in the first three quarters of 2024, compared to -¥186.26 million in the same period of 2023, indicating a worsening cash flow situation[21] Research and Development - Research and development expenses for the first three quarters of 2024 amounted to CNY 72,715,184.45, representing a 16.4% increase from CNY 62,670,894.08 in the same period of 2023[15] - The company reported a significant increase in R&D expenses to ¥30,744,470.05, compared to ¥29,148,881.33 in the same period last year, indicating a focus on innovation[25] Shareholder Information - The company has a total of 15,544 common shareholders at the end of the reporting period[8] - The largest shareholder, Xu Jiangnan, holds 46.51% of the shares, totaling 203,603,970 shares[7] - The company has no significant changes in the participation of major shareholders in margin trading or stock lending[8] Operational Insights - The increase in revenue and profit was primarily driven by higher sales of vitamin products during the reporting period[6] - Non-recurring gains and losses for the period totaled ¥10,907,652.66, with significant contributions from government subsidies and fair value changes of financial assets[5] - There are no other significant reminders regarding the company's operational situation during the reporting period[9] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[29]